Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 4, 2007, Pages 201-211

  Wang, Xin ^a   Yamataka, Kazunobu ^a,b   Okamoto, Mika ^a   Ikeda, Satoru ^b   Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b JAPAN TOBACCO INC   (Japan)

Author keywords

CDK9 cyclin T1; HIV 1; Naphthalene derivative; NF B; Tat

Indexed keywords

ANTIVIRUS AGENT; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JTK 101; K 37; LAMIVUDINE; NAPHTHALENE DERIVATIVE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; MACROPHAGE; MESSENGER RNA SYNTHESIS; MONOCYTE; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 34848903905     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800404     Document Type: Article

References (32)

1. Alcami J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, Virelizier JL & Arenzana-Seisdedos F (1995). Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. The EMBO Journal 14:1552-1560.
2. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T & Okamoto T (1998). Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Molecular Pharmacology 53:1097-1103.
3. Baba M, Okamoto M & Takeuchi H (1999). Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species. Antimicrobial Agents & Chemotherapy 43:2350-2355.
4. Biswas DK, Salas TR, Wang F, Ahlers CM, Dezube BJ & Pardee AB (1995). A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. Journal of Virology 69:7437-7444.
5. + cell model of chronic infection. Journal of Virology 65:4645-4653.
6. Cullen BR (1991). Regulation of human immunodeficiency virus replication. Annual Review of Microbiology 45:219-250.
7. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD & Siliciano RF (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
8. Heredia A, Davis C, Bamba D, Le N, Gwarzo MY, Sadowska M, Gallo RC Sc Redfield RR (2005). Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19:2087-2095.
9. Herrmann CH & Rice AP (1995). Lentivirus Tat proteins specifically associated with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. Journal of Virology 69:1612-1620.
10. Herrmann CH, Carroll RG, Wei P, Jones KA & Rice AP (1998). Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. Journal of Virology 72:9881-9888.
11. Jones KA & Peterlin BM (1994). Control of RNA initiation and elongation at the HIV-1 promoter. Annual Review of Biochemistry 63:717-743.
12. Liou LY, Herrmann CH & Rice AP (2002). Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. Journal of Virology 76:10579-10587.
13. Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y, Peng J, Blau C, Hazuda D, Price D & Flores O (1997). P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes & Development 11:2633-2644.
14. Nobel G & Baltimore D (1987). An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713.
15. Okamoto H, Cujec TP, Okamoto M, Peterlin BM, Baba M & Okamoto T (2002). Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272:402-408.
16. Okamoto T (1995). Regulatory proteins of human immunodeficiency virus and therapy, in Anti-AIDS drug development: challenges, strategies and prospects. In Anti-AIDS drug development: challenges, strategies and prospects. Edited by P Mohan and M Baba. Switzerland: Harwood Academic Publishers, pp.117-127.
17. Parolin C, Gatto B, Del Vecchio C, Pecere T, Tramontano E, Cecchetti V, Fravolini A, Masiero S, Palumbo M & Palu G (2003). New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrobial Agents & Chemotherapy 47:889-896.
18. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988). Rapid and automated tetrazolium based colorimetric assay for detection of anti-HIV compounds. Journal of Virological Methods 20:309-312.
19. Peng J, Zhu Y, Milton JT & Price DH (1998). Identification of multiple cyclin subunits of human P-TEFb. Genes & Development 12:755-762.
20. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, Hao Z, Gerrard TL, Wilson YA, Johns DG & Broder S (1988). Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and human peripheral blood monocyte/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. The Journal of Experimental Medicine 168:1111-1125.
21. Peterlin BM & Trono D (2003). Hide, shield and strike back: how human immunodeficiency virus-infected cells avoid immune eradication. Nature Reviews Immunology 3:97-107.
22. Pierson T, McArthur J & Siliciano RF (2000). Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annual Review of Immunology 18:665-708.
23. Pomerantz RJ & Horn DL (2003). Twenty years of therapy for HIV-1 infection. Nature Medicine 9:867-873.
24. Price DH (2000). P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Molecular & Cellular Biology 20:2629-2634.
25. Richter S, Parolin C, Gatto B, Del Vecchio C, Brocca-Cofano E, Fravolini A, Palu G & Palumbo M (2004). Inhibition of human immunodeficiency virus type 1 Tat-trans-activation-responsive region interaction by an antiviral quinoline derivative. Antimicrobial Agents & Chemotherapy 48:1895-1899.
26. Roulston A, Lin R, Beauparlant P, Wainberg MA & Hiscott J (1995). Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-κB/Rel transcription factors. Microbiological Reviews 59:481-505.
27. Stevens M, Balzarini J, Lagoja IM, Noppen B, François K, Van Aerschot A, Herdewijn P, De Clercq E & Pannecouque C (2007). Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives. Virology 356:220-237.
28. Wang X, Miyake H, Okamoto M, Saito M, Fujisawa J, Tanaka Y, Izumo S & Baba M (2002). Inhibition of the Tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative K-37. Molecular Pharmacology 61:1359-1365.
29. Wang D, de la Fuente C, Deng L, Wang L, Zilberman I, Eadie C, Healey M, Stein D, Denny T, Harrison LE, Meijer L & Kashanchi F (2001). Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. Journal of Virology 75:7266-7279.
30. Wei P, Garber ME, Fang SM, Fisher WH & Jones KA (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
31. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA & Richman DD (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
32. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S & Volberding PA (2004). Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. The Journal of the American Medical Association 292:251-265.